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Construction of a Meroterpenoid-like Compounds Library 
Based on Diversity-Enhanced Extracts 
Haruhisa Kikuchi,*[a] Kosuke Kawai,[a] Yota Nakashiro,[a] Takayuki Yonezawa,[b] Kumi Kawaji,[c] Eiichi N. 
Kodama[c] and Yoshiteru Oshima[a] 
Abstract: The structural diversity of natural products and their 
derivatives have long contributed to the development of new drugs. 
However, the difficulty in obtaining compounds bearing skeletally 
novel structures has recently led to the decline of pharmaceutical 
research into natural products. In this paper, we report the 
construction of a meroterpenoid-like library containing 25 compounds 
with diverse molecular scaffolds obtained from diversity-enhanced 
extracts. This method constitutes an approach for increasing the 
chemical diversity of natural-product-like compounds by combining 
natural product chemistry and diversity-oriented synthesis. Extensive 
pharmacological screening of the library revealed promising 
compounds for anti-osteoporotic and anti-lymphoma/leukemia drugs. 
This result indicates that the use of diversity-enhanced extracts is an 
effective methodology for producing chemical libraries for the purpose 
of drug discovery. 
Introduction 
Natural products and their derivatives have long played an 
essential role in the development of novel drugs because of their 
structural diversity. However, pharmaceutical research into 
natural products has recently declined because of factors such as 
more difficulty of collecting novel compounds with skeletally novel 
structures from natural resources than from combinatorial 
synthetic libraries.1,2 Therefore, new approaches for augmenting 
the chemical diversity of these compounds are crucial to retaining 
the usefulness of natural products and their derivatives. 
Recently, we proposed the use of “diversity-enhanced 
extracts”,3,4 which is an approach for increasing the chemical 
diversity of natural-product-like compounds through a 
combination of natural product chemistry and diversity-oriented 
synthesis.5 Diversity-enhanced extracts are obtained from 
chemical reactions that remodel molecular scaffolds directly in the 
extracts of natural resources. The subsequent isolation of each 
compound produced from such reactions affords a diverse 
natural-product-like library of new molecular scaffolds. There 
have also been some reports on similar methods that chemically 
convert natural extracts.6–11 However, we defined diversity-
enhanced extracts as natural extracts formed by multiple 
diversity-generating reactions that not only convert functional 
groups, but also form new carbon–carbon bonds and modify the 
molecular scaffolds similarly to diversity-oriented synthesis. 
Meroterpenoids are natural products of mixed biosynthetic origin 
that are partially derived from terpenoids.12a Particularly, 
meroterpenoids derived from polyketide and terpenoid precursors 
contain sp3-rich terpenoid scaffolds and sp2-rich polyketide 
scaffolds, which confer various pharmacological activities. 
Meroterpenoids are often isolated from fungi and marine 
organisms. On the other hand, plants can produce limited types 
of meroterpenoids, such as cannabinoids and polyprenylated 
phloroglucinols,12 though plants are rich sources of several types 
of terpenoids. If meroterpenoid-like compounds based on 
terpenoids derived from plants can be produced, then they can be 
useful in constructing a chemically diverse compound library for 
drug discovery. 
 In this paper, we report the construction of a library of 
meroterpenoid-like compounds with diverse scaffolds based on 
the diversity-enhanced extracts of classical medicinal plants. 
Among these compounds, anti-osteoporotic and antiviral 
compounds were obtained via extensive pharmacological 
screening. 
Results and Discussion 
Preparation of diversity-enhanced natural extracts. 
Although typically diverse in structure, phenolic meroterpenoids 
such as siccanin13 and pyrone-type meroterpenoids such as 
pyripyropene A14 possess polyketide-derived meroterpenoid 
structures. More specifically, they contain a cyclic ether moiety 
fused with a benzene or pyrone ring (Scheme 1). Thus, we 
planned to construct such cyclic ether moieties to produce 
meroterpenoid-like compounds in diversity-enhanced extracts. 
Two successive reactions, ortho-iodophenyl etherification of allyl 
or homoallyl alcohol moiety in terpenoids and a ring formation by 
Mizoroki-Heck reaction15 would produce cyclic ether moieties in 
phenolic meroterpenoid-like compounds. Reacting these 
compounds with iodo-a-pyrone instead of o-iodophenol would 
result in the formation of pyrone-type meroterpenoids. 
Cyperus rotundus is a traditional medicinal plant used as both 
an antipyretic and an aromatic stomatic. The main constituents of 
C. rotundus are sesquiterpenoids such as a-cyperone and 
cyperotundone, which contain an allyl alcohol or a,b-unsaturated 
ketone moiety.16 Methanol extracts of C. rotundus were treated 
with DIBAL to produce chemically reduced extracts. The use of  
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Scheme 1. Synthetic route for obtaining meroterpenoid-like compounds. 
such conditions enabled the reduction of a,b-unsaturated ketones 
into the allyl alcohols. Next, the etherification of the allyl alcohols 
was carried out by Mitsunobu reaction with methyl 4-hydroxy-3-
iodobenzoate in the presence of N,N,Nʹ,Nʹ-
tetramethylazodicarboxyamide and tributylphosphine17 to afford 
mixtures of aryl ethers. Finally, these mixtures were subjected to 
intramolecular Mizoroki–Heck reaction conditions to obtain 
diversity-enhanced extracts containing phenolic meroterpenoid-
like compounds with cyclic ether moieties (Scheme 2). On the 
other hand, the etherification of the chemically reduced extracts 
using 4-hydroxy-3-iodo-6-methyl-2H-pyran-2-one instead of 
iodobenzoate was carried out to produce diversity-enhanced 
extracts containing pyrone-type meroterpenoid-like compounds. 
Curcuma zedoaria,18 Curcuma longa,19 and Atractylodes 
japonica20 are also traditional medicinal plants that are rich 
sources of sesquiterpenoids. Diversity-enhanced extracts 
containing meroterpenoid-like compounds were also prepared 
from the methanol extracts of these medicinal plants using similar 
procedures. 
 
Isolation and structure elucidation of phenolic 
meroterpenoids. 
The diversity-enhanced extracts of C. rotundus, C. zedoaria, C. 
longa, and A. japonica conjugated with hydroxyiodobenzoates 
were separated by repeated column chromatography. Five 
phenolic meroterpenoid-like compounds (1–5) were isolated from 
the extracts of C. rotundus (Scheme 2), while five (6–10), four 
(11–14), and two (15, 16) compounds were isolated from those of 
C. zedoaria, C. longa, and A. japonica, respectively. The 
structures including the relative stereochemistry of these 
compounds were established using NMR spectroscopy (see 
Supporting Information). The isolated compounds are assumed 
to be produced from the constituents of their plant sources 
(Scheme S1~4). For example, compound 1 is assumed to be 
produced from cyperotundone,16a a constituent of C. rotundus, via 
reduction, etherification, and cyclization, as expected (Scheme 
3A). Because the stereochemistry at C-1, C-7, and C-10 should 
be retained through these reactions, the absolute configurations 
at C-1, C-7, and C-10 in 1 are assumed to be R, R, and R,  
 
Scheme 2. Phenolic meroterpenoid-like compounds isolated from the diversity-
enhanced extracts of sesquiterpenoid-containing medicinal plants. 
respectively, which are the same as those in cyperotundone. 
Compounds 2, 4, and 5 are assumed to be produced from a-
cyperone or cyperol,16b even though cyclic ether moieties were 
not formed in 4 and 5. On the other hand, some isolated 
compounds are assumed to be produced by unexpected 
reactions. For example, compound 6 is produced from 
germacrone,18d a constituent of C. zedoaria, by sequential 
reduction, etherification, cyclization, and additional 
Cope rearrangement21 (Scheme 3B). Compounds 7 and 8 are 
produced from curzerenone by sequential reduction, etherification, 
and bicyclization caused by tandem Mizoroki–Heck reactions 
(Scheme 3C). Compound 15 is produced from selina-4(14),7(11)-
dien-8-one20b via SN2ʹ-type Mitsunobu etherification (Scheme 3D). 
Compound 16 is produced from atractylenolide II with the 
elimination of Pd(OH)I at Mizoroki–Heck reaction (Scheme 3E). 
Siccanin
O
O
HO
H A typical structural moiety of
phenolic meroterpenoids
O
O
N
O
HAcO OAc
HO
AcO
A typical structural moiety of
pyrone-type meroterpenoids Pyripyropene A
OH
n
O
n
I
O
n
O
I
O
HO
I
O
HO
I
O
n
O
n
O
O
O
An allyl or homoallyl alcohol
moiety in terpenoids
Mitsunobu
phenyl etherification
Mizoroki-
Heck reaction
R R
R R
RR
1
Separation
by chromatography
Diversity-enhanced
extracts
Extraction
Methanol extracts
Ag2CO3, toluene, 110 ˚C
PdCl2(dppf)•CH2Cl2
Mixtures of
phenyl ethers
From Curcuma zedoaria
From Cyperus rotundus
11
12
Terpenoid-
containing
plants
DIBAL
THF, 0˚C
HO
I
OMe
O
TMAD, Bu3P, toluene, rt
by MeOH
Reduced extracts
O
O
MeO
H
O
O
MeO
O
MeO
O
H
H O
O
MeO
O
H
MeO
O
O
MeO
O
O
MeO
O
O
OMeO
O
MeO
O
O
MeO
O
O
OMeO
From Curcuma longa From Atractylodes japonica
2
3
4
5
6 7 8
9 10
13
14
15
16
O
O
OMe
H
O
O
H
MeO
O
O
O
H
O
OH
MeO
O
O
MeO
OH
H
HOH
O
MeO
O
OH
H
H
FULL PAPER    
 
 
 
 
 
 
 Scheme 3. Plausible pathways for the synthesis of phenolic meroterpenoid-like 
compounds 1, 6, 7, 8, 15 and 16. 
Isolation and structure elucidation of pyrone-type 
meroterpenoids. 
The diversity-enhanced extracts of C. rotundus, C. longa, and 
A. japonica conjugated with hydroxyiodopyrones were separated 
by repeated column chromatography. Four pyrone-type 
meroterpenoids (17–20) were isolated from the extracts of C. 
rotundus (Scheme 4), while three (21–23) and two (24, 25) 
compounds were isolated from those of C. longa and A. japonica, 
respectively. These isolated compounds are also assumed to be 
produced from the constituents of their plant sources (see 
Supporting Information). Compound 24 is formed from selina-
4(14),7(11)-dien-8-one via reduction, etherification, and 
cyclization, as expected. Cyclic ether moieties were not formed in 
compounds 18, 20, and 25, although the triangle triquinane 25 is 
assumed to be produced from 3a,5a,8-trimethyl-
1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene-4-carboxylic 
acid, which has been previously reported to be a constituent of 
Ligularia caloxantha.22 Compounds 17, 21, and 22 are produced 
through SN2ʹ-type Mitsunobu etherification. On the other hand, 19 
is assumed to be produced from cyperotundone through C–C 
bond formation under Mitsunobu reaction conditions resulting in 
hydroiodination, followed by Wacker-type oxidation and the 
transfer of double bonds (Scheme 5).  
Scheme 4. Pyrone-type meroterpenoids isolated from the diversity-enhanced 
extracts of sesquiterpenoid-containing medicinal plants. 
 
Scheme 5. Plausible pathways for the synthesis of pyrone-type meroterpenoid 
19. 
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Evaluation of the chemical diversity of the meroterpenoid-
like compound library. 
We evaluated the chemical diversity of the meroterpenoid-like 
compound library by calculating Tanimoto coefficients based on 
2D molecular fingerprints.23 A Tanimoto coefficient is obtained for 
a pair of compounds on a scale of 0 to 1, with 0 and 1 representing 
perfect dissimilarity and similarity, respectively. It has been 
reported that the Tanimoto coefficient is generally greater than 0.7 
between a parent compound and its simply modified compound 
(e.g., following alkylation, oxidation/reduction, and substitution of 
functional groups).24,25 A similarity matrix for the meroterpenoid-
like library (Figure 1) shows that the average of the calculated 
Tanimoto coefficients is 0.230, indicating that the meroterpenoid-
like compounds in the library are structurally different from one 
another. The averages of the groups of phenolic (1–16) and 
pyrone-type meroterpenoids (17–25) are 0.318 and 0.268, 
respectively, indicating that these compounds, in which the same 
polyketide moiety has been introduced, are also structurally 
different from one another. Thus, the use of the diversity-
enhanced extracts produced a structurally diverse 
meroterpenoid-like library, which cannot be obtained solely by 
simple modification of known natural products. 
Figure 1. Matrix of Tanimoto coefficients for the meroterpenoid-like library 
obtained from the diversity-enhanced extracts. The Tanimoto coefficients were 
calculated using KNIME® Analytic Platform version 3.5.2 based on ECFP4 
molecular fingerprints. The fingerprints of compounds 4 and 5 are identical 
because they are diastereomeric. 
Evaluation of the biological activities of the meroterpenoid-
like compound library. 
To verify the usefulness of the library of meroterpenoid-like 
compounds for drug discovery and to discover new 
pharmacologically active compounds, the library was extensively 
screened for biological activities. As a result, some compounds in 
the library have been found to have two types of biological 
activities. 
Osteoclasts are multinucleated cells that resorb bone tissue. 
They are formed by the fusion of mononuclear 
monocyte/macrophage lineage precursor cells. Excessive bone 
resorption often results in osteoporosis and rheumatoid arthritis.26 
To assess the effect on osteoclastogenesis, monocytic 
RAW264.7 cells were treated with the meroterpenoid-like 
compounds in the presence of receptor activator of NF-kB ligand 
(RANKL) and measured activity of tartrate-resistant acid 
phosphatase (TRAP), which is an osteoclast specific marker 
enzyme.27 We found that compound 16 suppressed RANKL-
induced TRAP activity with an IC50 value of 6.2 µM (Figure 2 and 
Figure S1) without showing cytotoxicity at the effective 
concentrations (data not shown); this suggests that compound 16 
is an inhibitor of osteoclastogenesis and a possible lead 
compound for the development of new drugs for treating 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Osteoclastogenesis-suppressive activity of compound 16. RAW264.7 
cells were treated with various concentrations of 16 in the presence of the 
receptor activator of the NF-kB ligand (RANKL) for four days. After fixation with 
10% formalin and 100% ethanol, TRAP activity was measured. Data are 
expressed as percentages in relation to the mean value of the control cells. The 
bars indicate the standard deviation of the three wells. The statistical 
significance of the differences was determined by Dunnett’s test. **p < 0.01 vs. 
control. 
The Epstein–Barr virus (EBV) has been strongly associated with 
the onset of several types of cancer, including both B-cell and 
T/NK-cell lymphomas.28 Because EBV infection is prevalent 
worldwide, the development of new anti-EBV drugs or drugs for 
treating the associated tumors due to this virus is urgent.  We 
screened the meroterpenoid compound library using an EBV-
infected KAI3 cell line (T/NK-cell lymphoma) to find compounds 
that show selective toxicity against the lymphoma cells. As a 
result, 17 was found to show toxicity against KAI3 cells at a 
concentration of less than 0.5 µM. In addition, 17 exerted similar 
cytotoxic effects on an adult T-cell leukemia cell line, MT-2, 
without demonstrating apparent cytotoxicity to a hepatoma cell 
line, HepG2, at a concentration up to 5 µM. These results indicate 
that 17 has selective cytotoxic effects toward lymphoma/leukemia 
cells. 
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Conclusions 
We constructed a library of meroterpenoid compounds from the 
diversity-enhanced extracts of medicinal plants. The library 
contains 25 compounds that have diverse molecular scaffolds 
and are difficult to obtain by other synthetic methods, as they were 
derived from the combination of the original diverse natural 
products of medicinal plants and diversity-generating reactions. 
The structural diversity of the compounds in the library was 
confirmed by using a Tanimoto similarity matrix. In the preparation 
of diversity-enhanced extracts, almost all compounds present in 
the natural extracts may be converted. Thus, unexpected and 
unique compounds such as 25 can be obtained by the conversion 
of undiscovered minor components that are present in the natural 
extracts. The occurrence of unexpected sequenced reactions 
also provided unexpected unique compounds, which enhanced 
the structural diversity of the compounds in the library. The 
isolation of each meroterpenoid-like compound from the diversity-
enhanced extracts may appear tedious in comparison with 
common chemical synthetic procedures, but only two to three 
successive column chromatography steps were necessary to 
separate these products, similar to the methods utilized for the 
isolation of common natural products. To expand the chemical 
diversity of the compound library, more meroterpenoid-like 
compounds will be obtained by using other types of terpenoid-
containing plants as starting materials. The use of structure-
modifying chemicals other than 2-iodophenol or iodopyrone will 
also produce more diverse meroterpenoid-like compounds. After 
extensive pharmacological screening of the meroterpenoid-like 
compounds, 16 and 17 were identified as seed compounds for 
anti-osteoporosis and selective anti-lymphoma/leukemia drugs, 
respectively. This result indicates that the use of diversity-
enhanced extracts is an effective methodology for constructing 
chemical libraries that may be screened for biologically active 
compounds. 
Experimental Section 
Preparation of phenolic meroterpenoids-containing diversity-
enhanced extracts. Rhizomes (209 g) of Cyperus rotundus, which was 
purchased from Kinokuniyakanyakkyoku Co., Ltd. (Tokyo, Japan), were 
extracted twice with methanol (1.60 L) at room temperature to give the 
extract. This extract was partitioned with ethyl acetate and water to yield 
the ethyl acetate solubles (13.14 g). 
Diisobutylaluminium hydride (1.0 M solution in toluene) (80 mL) was 
added to a solution of the ethyl acetate solubles (8.55 g) in THF (80 mL) 
at 0 ˚C. After being stirred for 3 hours at 0 ˚C, the reaction mixture was 
poured into saturated potassium sodium tartarate solution, and the mixture 
stirred for 30 minutes. Then, the mixture was extracted with ethyl acetate 
three times. The combined organic layer was washed with water and brine, 
dried over sodium sulfate, and concentrated in vacuo to the reduced 
extracts (7.52 g). 
Tri-n-butylphosphine (2.5 mL, 10 mmol) was added dropwise to the 
solution of N,N,Nʹ,Nʹ-tetramethylazodicarboxyamide (1.72 g, 10 mmol) in 
toluene (10 mL) at 0 ˚C. Then, the solution of the reduced extracts (3.00 
g) and methyl 4-hydroxy-3-iodobenzoate (1.47 g, 5.30 mmol) in toluene 
(20 mL) was added dropwise to the reaction mixture. After being stirred for 
12 hours at room temperature, the mixture was extracted with ethyl acetate 
three times. The combined organic layer was washed with water and brine, 
dried over sodium sulfate, and concentrated in vacuo. The residue was 
chromatographed over silica gel eluted by hexane-ethyl acetate (19:1 to 
4:1) to the mixture of phenyl ethers (1.83 g). 
The mixture of phenyl ethers (1.83 g), PdCl2(dppf) complex with 
dichloromethane (196 mg, 0.24 mmol), 1,1’-
bis(diphenylphosphino)ferrocene (266 mg, 0.48 mmol) and silver 
carbonate (1.65 g, 6.0 mmol) were suspended in toluene (25 mL), and the 
mixture was refluxed for 12 hours under argon atmosphere. After being 
cooled into room temperature, the reaction mixture was filtered through a 
silica gel pad, which was eluted by ethyl acetate. The filtrate was 
concentrated in vacuo to afford the diversity-enhanced extracts containing 
phenolic meroterpenoid-like compounds (476 mg). 
By the use of the same procedure described above, the phenolic 
meroterpenoids-containing diversity enhanced extracts of Curcuma 
zedoaria (570 mg), Curcuma longa (2.99 g) and Atractylodes japonica 
(1.00 g) were afforded from the methanol extracts of rhizomes of C. 
zedoaria (101 g), C. longa (151 g) and A. japonica (150 g), respectively. 
Separation of the phenolic meroterpenoids-containing diversity-
enhanced extracts of C. rotundus. The diversity-enhanced extracts (476 
mg) of C. rotundus were chromatographed over silica gel and the column 
eluted with hexane-ethyl acetate mixtures with increasing polarity to afford 
hexane-ethyl acetate (19:1) eluent (fraction A, 201 mg), which was further 
separated by ODS column using water-acetonitrile solvent system to give 
water-acetonitrile (3:7) eluent (fraction A-1, 16.6 mg), water-acetonitrile 
(2:8) eluent (fraction A-2, 53.0 mg) and water-acetonitrile (1:9) eluent 
(fraction A-3, 11.1 mg). 
Fraction A-1 was subjected to recycle preparative HPLC (column, YMC-
GPC T-2000 (f 20 mm x 600 mm, YMC Co., Ltd.); solvent, ethyl acetate) 
to give compound 3 (1.8 mg). Fraction A-2 was also subjected to recycle 
preparative HPLC (column, YMC-GPC T-2000 (f 20 mm x 600 mm, TMC 
Co., Ltd.); solvent, ethyl acetate) to give compounds 1 (5.4 mg) and 2 (4.3 
mg). Fraction A-3 was subjected to reverse phase HPLC (column, 
Wakopak Navi C30-5 (f 20 mm x 250 mm, Wako Pure Chemical Industries, 
Ltd.); solvent, water–acetonitrile (9:1)) to give compounds 4 (5.3 mg) and 
5 (2.8 mg). 
Preparation of pyrone-type meroterpenoids-containing diversity-
enhanced extracts. Tri-n-butylphosphine (3.7 mL, 15 mmol) was added 
dropwise to the solution of N,N,Nʹ,Nʹ-tetramethylazodicarboxyamide (2.58 
g, 15 mmol) in toluene (10 mL) at 0 ˚C. Then, the solution of the reduced 
extracts of C. rotundus (3.24 g) and 4-hydroxy-3-iodo-6-methyl-2-pyrone 
(2.51 g, 10.0 mmol) in toluene (30 mL) was added dropwise to the reaction 
mixture. After being stirred for 12 hours at room temperature, the mixture 
was extracted with ethyl acetate three times. The combined organic layer 
was washed with water and brine, dried over sodium sulfate, and 
concentrated in vacuo. The residue was chromatographed over silica gel 
eluted by hexane-ethyl acetate (2:1 to 1:3) to the mixture of pyronyl ethers 
(1.74 g). 
The mixture of pyronyl ethers (1.74 g), PdCl2(dppf) complex with 
dichloromethane (183 mg, 0.22 mmol), 1,1’-
bis(diphenylphosphino)ferrocene (251 mg, 0.45 mmol) and silver 
carbonate (1.54 g, 5.6 mmol) were suspended in toluene (20 mL), and the 
mixture was refluxed for 12 hours under argon atmosphere. After being 
cooled into room temperature, the reaction mixture was filtered through a 
silica gel pad, which was eluted by ethyl acetate. The filtrate was 
concentrated in vacuo to afford the diversity-enhanced extracts containing 
pyrone-type meroterpenoids (1.07 g). 
By the use of the same procedure described above, the pyrone-type 
meroterpenoids-containing diversity enhanced extracts of Curcuma longa 
(3.15 g) and Atractylodes japonica (1.05 g) were afforded from the 
methanol extracts of rhizomes of C. zedoaria, C. longa and A. japonica, 
respectively. 
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Separation of the pyrone-type meroterpenoids-containing diversity-
enhanced extracts of C. rotundus. The diversity-enhanced extracts 
(1.07 g) were chromatographed over silica gel and the column eluted with 
hexane-ethyl acetate mixtures with increasing polarity to afford hexane-
ethyl acetate (19:1) eluent (fraction A, 100 mg), hexane-ethyl acetate (9:1) 
eluent (fraction B, 147 mg) and hexane-ethyl acetate (4:1) eluent (fraction 
C, 251 mg). 
Fraction A was separated by ODS column using water-acetonitrile 
solvent system to give water-acetonitrile (2:8) eluent (fraction A-1, 15 mg), 
which was subjected to recycle preparative HPLC (column, YMC-GPC T-
2000 (f 20 mm x 600 mm, TMC Co., Ltd.); solvent, ethyl acetate) to give 
compound 19 (5.1 mg). 
Fraction B was separated by ODS column using water-acetonitrile 
solvent system to give water-acetonitrile (4:6) eluent (fraction B-1, 11 mg) 
and water-acetonitrile (3:7) eluent (fraction B-2, 19 mg). Fraction B-1 was 
subjected to recycle preparative HPLC (column, YMC-GPC T-2000 (f 20 
mm x 600 mm, TMC Co., Ltd.); solvent, ethyl acetate) to give compounds 
17 (2.7 mg). Fraction B-2 was subjected to reverse phase HPLC (column, 
Mightysil RP-18GP (f 20 mm x 250 mm, Kanto Chemical Co., Inc.); solvent, 
water–acetonitrile (3:7)) to give compound 20 (1.0 mg). 
Fraction C was separated by ODS column using water-acetonitrile 
solvent system to give water-acetonitrile (3:7) eluent (fraction C-1, 16 mg), 
which was subjected to reverse phase HPLC (column, Mightysil RP-18GP 
(f 20 mm x 250 mm, Kanto Chemical Co., Inc.); solvent, water–acetonitrile 
(3:7)) to give compound 18 (9.0 mg). 
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